by Talha Khan Burki
The Lancet Oncology: Volume 20, Issue 1, PE13,
January 01, 2019
A new study has
concluded that adjuvant trastuzumab emtansine (T-DM1) reduces the risk of
recurrence or death in patients with HER2-positive breast cancer who have
residual disease after neoadjuvant therapy and surgery. In the phase 3,
open-label trial, women with HER2-positive, early-stage breast cancer had
received neoadjuvant therapy consisting of at least six cycles of chemotherapy,
including a taxane, and trastuzumab for at least 9 weeks. Patients were
randomly assigned to receive 14 cycles of either T-DM1 or trastuzumab (n=743
per group).
